TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TScan Therapeutics ( (TCRX) ) has issued an update.
On November 25, 2025, TScan Therapeutics‘ Board of Directors approved a retention program to secure key employees, including its CEO, CFO, and CMO, with cash and equity-based awards. This initiative aims to support the company’s operations and advance the pivotal trial of TSC-101, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (TCRX) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.
Spark’s Take on TCRX Stock
According to Spark, TipRanks’ AI Analyst, TCRX is a Neutral.
The overall stock score for TScan Therapeutics is primarily impacted by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. The technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively contribute to a low overall score.
To see Spark’s full report on TCRX stock, click here.
More about TScan Therapeutics
TScan Therapeutics, Inc. operates in the biotechnology industry, focusing on developing T-cell receptor-engineered T-cell therapies for the treatment of cancer.
Average Trading Volume: 672,186
Technical Sentiment Signal: Sell
Current Market Cap: $55.53M
See more data about TCRX stock on TipRanks’ Stock Analysis page.